The BLZF1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the basic leucine zipper (bZIP) transcription factor BLZF1 in the human hepatic adenocarcinoma cell line SK-HEP-1. This knockout model enables loss-of-function studies by abolishing BLZF1-mediated transcriptional regulation without introducing monoclonal selection, thereby preserving a heterogeneous genetic background that more closely mimics tumor cell diversity. The polyclonal pool is suitable for functional genomics screens, biochemical analyses, and downstream assays where population-level knockout phenotypes are desired.
SK-HEP-1 cells originate from a human hepatic adenocarcinoma and are widely utilized as a model system for hepatocellular carcinoma (HCC) research. These adherent epithelial cells exhibit a tumorigenic phenotype and retain key signaling pathways relevant to liver cancer pathogenesis, including JAK/STAT-mediated proliferation and survival signals. Their robust growth and well-characterized response to cytokine stimulation make them an ideal host for investigating transcription factor networks that drive malignancy. The SK-HEP-1 background provides a clinically relevant platform for evaluating the role of BLZF1 in liver tumor biology.
BLZF1 is a transcriptional regulator that functions as a core component of the bZIP transcription factor family, interacting with other bZIP proteins and transcriptional co-regulators to modulate gene expression. It is activated downstream of cytokine receptors such as the IL-2 receptor, through the JAK/STAT signaling pathway, where JAK2-mediated phosphorylation of STAT3 promotes its nuclear translocation and transcriptional activity. BLZF1 regulates a broad set of target genes, including cell cycle regulators and apoptosis-related factors, thereby influencing cellular proliferation and differentiation. Representative pathway components linking BLZF1 to IL-2 and IL-6 signaling include JAK2, STAT3, and the IL-2 receptor, underscoring its integration into hematopoietic and oncogenic signaling networks.
In the context of SK-HEP-1 hepatic adenocarcinoma cells, BLZF1 knockout disrupts the transcription factor??s ability to control gene programs that govern tumor cell growth and survival. Given BLZF1??s established role in hematopoietic differentiation and its association with leukemogenesis, its functional ablation in a liver cancer model may reveal convergent oncogenic mechanisms shared between hepatocellular carcinoma and hematologic malignancies. The knockout model is therefore significant for dissecting how BLZF1-dependent transcriptional alterations influence key malignant properties such as sustained proliferation, resistance to apoptosis, and metastatic potential in a solid tumor environment.
This polyclonal knockout cell product is suitable for a range of research applications including the investigation of BLZF1 in hepatocellular carcinoma proliferation, migration, and apoptosis, as well as drug sensitivity screening and transcriptional target identification. Representative assays that can be performed include Western blotting, RT-qPCR, cell proliferation and colony formation assays, transwell migration assays, apoptosis detection, and luciferase reporter assays for transcriptional activity. By providing a genetically defined loss-of-function model, the BLZF1 Knockout SK-HEP-1 Polyclonal Cells enable precise interrogation of BLZF1-mediated pathways and support the discovery of novel therapeutic vulnerabilities. For further technical details, please contact Ascent Research.
